Rapid Dose Therapeutics Begins Trading on the CSE Under the Ticker “DOSE”
December 17, 2018
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES..
Burlington Ontario – December 17, 2018. Rapid Dose Therapeutics Corp. (formerly ACME Resources Corp.) (CSE: DOSE) ("RDT" or the "Corporation") is pleased to announce that, following completion of the business combination with Rapid Dose Therapeutics Inc., the Corporation’s Common Shares will commence trading on the Canadian Securities Exchange (the "CSE") under the four-letter ticker symbol "DOSE" effective as of the opening of the market today.
RDT’s CEO, Mark Upsdell, commented that, "The RDT team is excited to begin trading on the Canadian Securities Exchange today. The RDT team is grateful to the former directors and officers of ACME Resources Corp. and to its shareholders for the genesis to what is a culmination of two years of efforts to create a world class bio-technology company. We would also like to express our gratitude to all those stakeholders and participants who have helped us reach this day, including but not limited to our industry partners, investors and advisors. We look forward to implementing our marketing and development strategy in order to realize the growth potential of this enterprise."
About the Corporation
A Game-Changing Delivery System
The Corporation is a Canadian bio-technology company which, through its subsidiaries, provides proprietary enhanced drug delivery technologies designed to improve patient outcomes. The Corporation, through its subsidiary, owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™, which is capable of rapidly releasing into the blood stream a variety of pharmaceuticals, emulsified oils and over-the-counter medicines without being degraded or modified by first pass metabolism in the liver. The Corporation, through its subsidiaries, also provides product innovation, production and consultation to the pharmaceutical and healthcare manufacturing industry.
Rapid Dose Therapeutics Corp.
1121 Walkers Line, Unit 3
Burlington ON Canada
Mark Upsdell, CEO
Telephone: (416) 477-1052
FORWARD-LOOKING STATEMENTS: Certain information contained in this news release may be forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are often, but not always identified by the use of words such as "expect", "anticipate", "believe", "foresee", "potential", "could", "estimate", "goal", "intend", "plan", "seek", "will", "may" and "should" and similar expressions or words suggesting future outcomes. This news release includes forward-looking information and statements pertaining to, among other things, certain anticipated strategic, operational, and competitive advantages and benefits created by the transaction and future opportunities for the Corporation.
Numerous risks and uncertainties could cause the actual events and results to differ materially from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements, including, but not limited to the anticipated strategic, operational and competitive benefits which may not be realized.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
Back to press releases page